Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides
Advertisement
Numaferm and Zoetis, an animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics. Financial details of the deal were not disclosed.
Pepteins are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a challenge for manufacturing, yet exert a high biological activity, wherefore they play an increasing role as innovative molecules in a range of industries, including animal and human health. To date, peptein production via chemical synthesis or recombinant approaches is cumbersome, leading to time and resource-intensive development programs. This, in combination with high production costs, limits promising peptein applications. The proprietary high-titer expression platform NumaswitchTM changes this situation and enables the access to pepteins within weeks.
“We appreciate Numaferm’s expertise in the expression of therapeutic proteins and peptides, which will enhance our internal capabilities in this field,” said Robert Polzer, Executive Vice President and President, Research and Development at Zoetis. “We look forward to working together to develop innovative therapeutics to meet the needs of our customers.”
Christian Schwarz, CEO at Numaferm GmbH said: “Our mission is supporting our partners with the best-in-class peptein technologies. The partnership collaboration with Zoetis is another milestone for Numaferm, demonstrating the value of our proprietary technologies for pharma projects and beyond.”
Other news from the department manufacturing
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly - Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform
Medigenomix Acquires an Exclusive License for another Genetic Polymorphisms in G-Proteins for Applications in Pharmacogenetics
Breakthrough: Prospect of blood test for Parkinson’s disease for the first time - A new method reliably detects protein changes in blood that are typical of Parkinson's disease: "The results are really sensational"
Evotec and Bayer partner to develop new treatments to fight kidney diseases
Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent
Vaccine-induced CD4 T cells have adverse effect in a mouse model of infection - Research offers a 'cautionary tale' for the development of CD4 T cell vaccines
Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b
Merck Plans to Invest € 1 Billion at the Darmstadt Site - Employment guarantee extended until the end of 2025
Agilent Technologies Announces Winner of Third Annual Early Career Professor Award
Graham Nicholls Joins Almac as Director of Biostatistics
Intercell starts a pivotal Phase II/III efficacy study with its Pseudomonas aeruginosa vaccine candidate
